Frequently Asked Questions about AC Immune S.A. (ACIU)

Name: AC Immune S.A. (ACIU) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does AC Immune S.A. (ACIU) do?

Accepted Answer

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, ...

Question 2

Is AC Immune S.A. (ACIU) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of ACIU reveals an Altman Z-Score of undefined and a Piotroski F-Score of undefined/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if ACIU fits their risk profile.

Question 3

What is the current P/E ratio for ACIU?

Accepted Answer

As of the latest trading session, AC Immune S.A. (ACIU) has a trailing P/E ratio of -3.58.

Question 4

Who is the CEO of AC Immune S.A.?

Accepted Answer

The current Chief Executive Officer of AC Immune S.A. is Andrea Pfeifer.

Question 5

What was ACIU's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, AC Immune S.A. reported annual revenues of $0.00B (2025), $0.03B (2024), $0.01B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does ACIU pay a dividend?

Accepted Answer

AC Immune S.A. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does ACIU have?

Accepted Answer

In its latest reporting period, AC Immune S.A. generated $-0.07B in Free Cash Flow against a total debt load of $0.00B.

Question 8

What is the Price-to-Book (P/B) ratio of AC Immune S.A.?

Accepted Answer

The Price-to-Book (P/B) ratio for AC Immune S.A. (ACIU) is currently 5.60.

Question 9

What is the Price-to-Sales (P/S) ratio of ACIU?

Accepted Answer

Based on trailing twelve-month data, AC Immune S.A. (ACIU) trades at a Price-to-Sales (P/S) ratio of 70.85.

Question 10

What is AC Immune S.A.'s Return on Equity (ROE)?

Accepted Answer

AC Immune S.A. (ACIU) has a Return on Equity (ROE) of -101.60%, representing its profitability relative to shareholder equity.

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	-66.1M	0	-859.5K	-67M	-67M
2024-12	65.8M	5.5M	-576K	65.3M	59.8M
2023-12	-60.4M	4.4M	-801K	-61.2M	-65.6M
2022-12	-73.6M	3.3M	-1.2M	-74.8M	-78.1M
2021-12	-65.7M	4.1M	-2.6M	-68.3M	-72.5M

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	-66.1M	0	-859.5K	-67M	-67M
2024-12	65.8M	5.5M	-576K	65.3M	59.8M
2023-12	-60.4M	4.4M	-801K	-61.2M	-65.6M
2022-12	-73.6M	3.3M	-1.2M	-74.8M	-78.1M
2021-12	-65.7M	4.1M	-2.6M	-68.3M	-72.5M